Shayesteh Fürst-Ladani is Head of the SFL Group and Senior Vice President of SFL.
Shayesteh has longstanding experience in providing comprehensive strategic advice for development of products including small molecules, biologics, drug & device combination products, medical devices, in vitro diagnostics (IVDs) and advanced therapy medicinal products (ATMPs). Shayesteh has distinguished capabilities in negotiating the interests of organizations at senior level meetings with regulators.
Shayesteh serves as President of the Board of Directors of the not-for-profit associations Rare Disease Action Forum (RDAF) and Medtech & Pharma Platform (MPP), and she lectures in Regulatory Affairs at the IFAPP Academy, Kings College London.
Before founding and leading SFL as CEO, Shayesteh held senior level positions at various biotech and pharmaceutical companies, including as Head of Global Regulatory Affairs and Head of Regulatory Affairs for Development Products. In 2022, Shayesteh Fürst-Ladani joined Veristat, following the acquisition of SFL to support a growing number of biotech, pharmaceutical and medtech companies.
Shayesteh received her MSc in Microbiology from the University of Vienna, Austria, and an MBA from the Open University Business School, Milton Keynes, UK. She is Global Fellow in Medicines Development (GFMD) from IFAPP.